新型降糖药物对2型糖尿病患者心脑血管事件影响的研究进展

doi:10.3969/j.issn.1673-5765.2021.07.017

摘要/Abstract

摘要： 2型糖尿病（type 2 diabetes mellitus，T2DM）是心脑血管疾病的独立危险因素，同时心血管疾病也是导致T2DM患者死亡的主要原因之一。近年来针对新型降糖药物的临床研究显示，胰高血糖素样肽-1受体激动剂可能对预防T2DM患者心脑血管事件有益；钠-葡萄糖共转运蛋白2抑制剂可降低糖尿病患者心血管事件和心力衰竭的风险，但降低脑血管事件风险的临床证据并不足；目前尚无二肽激肽酶-4抑制剂对T2DM患者心脑血管事件影响的可靠证据。因此，需要更多的临床研究来提供新型降糖药物对心脑血管事件，尤其是对脑血管事件发生和预后影响的临床证据。

文章导读： 本文对近年来GLP-1 RA、DPP-4I、SGLT2I三类新型降糖药物对T2DM患者心脑血管事件影响的临床证据进行了汇总讨论，对其临床应用价值进行了分析。

关键词: 心脑血管事件; 新型降糖药; 胰高血糖素样肽-1受体激动剂; 二肽激肽酶-4抑制剂; 钠-葡萄糖共转运蛋白2抑制剂

Abstract: Type 2 diabetes mellitus (T2DM) is an independent risk factor for cardio- and cerebrovascular diseases. Cardiovascular disease is also one of the main causes of death in T2DM patients. So it is important for T2DM patients to find new hypoglycemic drugs which also have cardio- and cerebrovascular protective effect. The recent studies about new hypoglycemic agents showed that glucagon-like peptide 1 receptor agonists (GLP-1 RA) may be beneficial for preventing cardio- and cerebrovascular events in T2DM patients. The clinical evidences showed that sodiumglucose cotransporter 2 inhibitor (SGLT2I) can reduce the risk of cardiovascular events and heart failure in T2DM patients, but the benefit evidence in cerebrovascular events is insufficient. There is no clear evidence that dipeptidyl peptidase 4 inhibitor (DPP-4I) can reduce the risk of cardioand cerebrovascular events. More researches were needed to provide the evidence of the effects of new hypoglycemic agents on cardio- and cerebrovascular events, especially for the occurrence and functional prognosis of stroke.

Key words: Cardiovascular and cerebrovascular event; New hypoglycemic agent; Glucagonlike peptide-1 receptor agonist; Dipeptidyl peptidase 4 inhibitor; Sodium-glucose cotransporter 2inhibitor

蔺建蕊, 崔向丽, 米东华, 李子孝, 赵性泉, 王拥军. 新型降糖药物对2型糖尿病患者心脑血管事件影响的研究进展[J]. 中国卒中杂志, 2021, 16(07): 739-745.

LIN Jian-Rui, CUI Xiang-Li, MI Dong-Hua, LI Zi-Xiao, ZHAO Xing-Quan, WANG Yong-Jun. Progress of Effects of New Hypoglycemic Drugs on Cardio- and Cerebrovascular Events in Patients with Type 2 Diabetes Mellitus[J]. Chinese Journal of Stroke, 2021, 16(07): 739-745.

参考文献

[1] WILCOX T，BLOCK C D，SCHWARTZBARD A
Z，et al. Diabetic agents，from metformin to SGLT2
Inhibitors and GLP1 receptor agonists[J]. J Am Coll
Cardiol，2020，75（16）：1956-1974.
[2] 苏工，高明喜，杨红霞. 2020年美国心脏病学会《降
低2型糖尿病患者心血管风险新型疗法的专家共识
决策路径》解读：降糖更要护心[J]. 中国全科医学，
2021，24（5）：509-516.
[3] ZHU J H，YU X X，ZHENG Y Y，et al. Association
of glucose-lowering medications with cardiovascular
outcomes：an umbrella review and evidence map[J].
Lancet Diabetes Endocrinol，2020，8（3）：192-205.
[4] 葛均波，霍勇，高秀芳，等. 改善心血管和肾脏结局的
新型抗高血糖药物临床应用中国专家建议[J]. 中国
循环杂志，2020，35（3）：231-238.

[5] MUSCOGIURI G，DEFRONZO R A，

GASTALDELLI A，et al. Glucagon-like peptide-1
and the central/peripheral nervous system：crosstalk
in diabetes[J]. Trends Endocrinol Metab，2017，28
（2）：88-103.
[6] 纪立农，邹大进，洪天配，等. GLP-1受体激动剂临
床应用专家指导意见[J]. 中国糖尿病杂志，2018，26
（5）：353-361.
[7] MARSO S P，DANIELS G H，BROWNFRANDSEN
K，et al. Liraglutide and cardiovascular
outcomes in type 2 diabetes[J]. N Engl J Med，2016，
375（4）：311-322.
[8] GERSTEIN H C，COLHOUN H M，DAGENAIS G
R，et al. Dulaglutide and cardiovascular outcomes
in type 2 diabetes（REWIND）：a double-blind，
randomised placebo-controlled trial[J]. Lancet，2019，
394（10193）：121-130.
[9] GERSTEIN H C，HART R，COLHOUN H M，et al.
The effect of dulaglutide on stroke：an exploratory
analysis of the REWIND trial[J]. Lancet Diabetes
Endocrinol，2020，8（2）：106-114.
[10] HOLMAN R R，BETHEL M A，MENTZ R J，et al.
Effects of once-weekly exenatide on cardiovascular
outcomes in type 2 diabetes[J]. N Engl J Med，2017，
377（13）：1228-1239.
[11] PFEFFER M A，CLAGGETT B，DIAZ R，et al.
Lixisenatide in patients with type 2 diabetes and
acute coronary syndrome[J]. N Engl J Med，2015，
373（23）：2247-2257.
[12] MARSO S P，HOLST A G，VILSBOLL T.
Semaglutide and cardiovascular outcomes in patients
with type 2 diabetes[J]. N Engl J Med，2017，376（9）：
891-892.
[13] HUSAIN M，BIRKENFELD A L，DONSMARK M，
et al. Oral semaglutide and cardiovascular outcomes
in patients with type 2 diabetes[J]. N Engl J Med，
2019，381（9）：841-851.
[14] MALHOTRA K，KATSANOS A H，
LAMBADIARI V，et al. GLP-1 receptor agonists in
diabetes for stroke prevention：a systematic review
and meta-analysis[J]. J Neurol，2020，267（7）：2117-
2122.
[15] American Diabetes Association. 9. Pharmacologic
approaches to glycemic treatment：standards of
medical care in diabetes-2019[J/OL]. Diabetes care，
2019，42（Suppl 1）：S90-S102[2020-12-11].
https：//doi.org/10.2337/dc19-s009.
[16] SANDEEP R D，BRENDAN M E，KIM K B，et al.
2020 Expert consensus decision pathway on novel
therapies for cardiovascular risk reduction in patients
with type 2 diabetes：a report of the American
College of Cardiology Solution Set Oversight
Committee[J]. J Am Coll Cardiol，2020，76（9）：
1117-1145.
[17] 中华医学会糖尿病学分会，中华医学会内分泌学分
会. 中国成人2型糖尿病合并心肾疾病患者降糖药
物临床应用专家共识[J]. 中华糖尿病杂志，2020，12
（6）：369-381.
[18] 中华医学会内分泌学分会，中华医学会糖尿病学分
会. 胰高糖素样肽-1（GLP-1）受体激动剂用于治疗2
型糖尿病的临床专家共识[J]. 中华内科杂志，2020，
59（11）：836-846.
[19] 中国医师协会内分泌代谢科医师分会. DPP-4抑制
剂临床应用专家共识[J]. 中华内分泌代谢杂志，2018，
34（11）：899-903.
[20] GREEN J B，BETHEL M A，ARMSTRONG P W，
et al. Effect of sitagliptin on cardiovascular outcomes
in type 2 diabetes[J]. N Engl J Med，2015，373（3）：
232-242.
[21] ROSENSTOCK J，PERKOVIC V，JOHANSEN
O E，et al. Effect of linagliptin vs placebo on
major cardiovascular events in adults with type 2
diabetes and high cardiovascular and renal risk：the
CARMELINA randomized clinical trial[J]. JAMA，
2019，321（1）：69-79.
[22] ROSENSTOCK J，KAHN S E，JOHANSEN O
E，et al. Effect of linagliptin vs glimepiride on
major adverse cardiovascular outcomes in patients
with type 2 diabetes：the CAROLINA randomized
clinical trial[J]. JAMA，2019，322（12）：1155-1166.
[23] WHITE W B，CANNON C P，HELLER S R，et al.
Alogliptin after acute coronary syndrome in patients
with type 2 diabetes[J]. N Engl J Med，2013，369
（14）：1327-1335.
[24] SCIRICA B M，BHATT D L，BRAUNWALD E，
et al. Saxagliptin and cardiovascular outcomes in
patients with type 2 diabetes mellitus[J]. N Engl J
Med，2013，369（14）：1317-1326.
[25] 纪立农，郭立新，郭晓蕙，等. 钠-葡萄糖共转运蛋白
2（SGLT2）抑制剂临床合理应用中国专家建议[J]. 中
国糖尿病杂志，2016，24（10）：865-870.
[26] ZINMAN B，WANNER C，LACHIN J M，et
al. Empagliflozin，cardiovascular outcomes，and
mortality in type 2 diabetes[J]. N Engl J Med，2015，
373（22）：2117-2128.
[27] NEAL B，PERKOVIC V，MATTHEWS D R.
Canagliflozin and cardiovascular and renal events
in type 2 diabetes[J]. N Engl J Med，2017，377（21）：
2099.
[28] PERKOVIC V，JARDINE M J，NEAL B，et al.
Canagliflozin and renal outcomes in type 2 diabetes
and nephropathy[J]. N Engl J Med，2019，380（24）：
2295-2306.

[29] FURTADO R，BONACA M P，RAZ I，et al.
Dapagliflozin and cardiovascular outcomes in
patients with type 2 diabetes mellitus and previous
myocardial infarction[J]. Circulation，2019，139
（22）：2516-2527.
[30] MCMURRAY J J，SOLOMON S D，INZUCCHI S E，
et al. Dapagliflozin in patients with heart failure and
reduced ejection fraction[J]. N Engl J Med，2019，381
（21）：1995-2008.
[31] PACKER M，ANKER S D，BUTLER J，et al.
Influence of neprilysin inhibition on the efficacy
and safety of empagliflozin in patients with chronic
heart failure and a reduced ejection fraction：the
EMPEROR-Reduced trial[J]. Eur Heart J，2021，42
（6）：671-680.
[32] HEERSPINK H J L，STEFÁNSSON B V，
CORREA-ROTTER R，et al. Dapagliflozin in
patients with chronic kidney disease[J]. N Engl J
Med，2020，383（15）：1436-1446.
[33] BHATT D L，SZAREK M，STEG P G，et al.
Sotagliflozin in patients with diabetes and recent
worsening heart failure[J]. N Engl J Med，2020，384
（2）：117-128.
[34] BHATT D L，SZAREK M，PITT B，et al.
Sotagliflozin in patients with diabetes and chronic
kidney disease[J]. N Engl J Med，2020，384（2）：
129-139.
[35] IMPRIALOS K P，BOUTARI C，STAVROPOULOS
K，et al. Stroke paradox with SGLT-2 inhibitors：a
play of chance or a viscosity-mediated reality?[J]. J
Neurol Neurosurg Psychiatry，2017，88（3）：249-
253.
[36] FRANCESCO C，GRANT P J，VICTOR A，et al.
2019 ESC Guidelines on diabetes，pre-diabetes，and
cardiovascular diseases developed in collaboration
with the EASD[J]. Eur Heart J，2019，41（2）：255-
323.
[37] ADRIAN L，SUNITA B，NARAYAN P，et al.
Asian pacific society of nephrology clinical practice
guideline on diabetic kidney disease[J]. Nephrology
（Carlton），2020，25（11）：809-817.
[38] Kidney Disease：Improving Global Outcomes
KDIGO Diabetes Work Group. KDIGO 2020 clinical
practice guideline for diabetes management in
chronic kidney disease[J/OL]. Kidney Int，2020，98
（4S）：S1-S115[2020-12-11]. https：//doi.org/10.1016/j.
kint.2020.06.019.
[39] MCDONALD M，VIRANI S，CHAN M，et al. CCS/
CHFS heart failure guidelines update：defining a
new pharmacologic standard of care for heart failure
with reduced ejection fraction[J]. Can J Cardiol，
2021，37（4）：531-546.
[40] WU J H，FOOTE C，BLOMSTER J，et al. Effects
of sodium-glucose cotransporter-2 inhibitors on
cardiovascular events，death，and major safety
outcomes in adults with type 2 diabetes：a systematic
review and meta-analysis[J]. Lancet Diabetes
Endocrinol，2016，4（5）：411-419.
[41] GUO M，DING J Y，LI J S，et al. SGLT2 inhibitors
and risk of stroke in patients with type 2 diabetes：a
systematic review and meta-analysis[J]. Diabetes
Obes Metab，2018，20（8）：1977-1982.
[42] HUSSEIN H，ZACCARDI F，KHUNTI K，et
al. Cardiovascular efficacy and safety of sodiumglucose
co-transporter-2 inhibitors and glucagonlike
peptide-1 receptor agonists：a systematic review
and network meta-analysis[J]. Diabet Med，2019，36
（4）：444-452.
[43] MCKEE A，AL-KHAZAALI A，ALBERT S G.
Glucagon-like peptide-1 receptor agonists versus
sodium-glucose cotransporter inhibitors for
treatment of T2DM[J/OL]. J Endocr Soc，2020，4（5）：
bvaa037[2020-12-11]. https：//doi.org/10.1210/jendso/
bvaa037.
[44] SINHA B，GHOSAL S. Meta-analyses of the
effects of DPP-4 inhibitors，SGLT2 inhibitors and
GLP1 receptor analogues on cardiovascular death，
myocardial infarction，stroke and hospitalization
for heart failure[J/OL]. Diabetes Res Clin Pract，
2019，150：8-16[2020-12-11]. https：//doi.org/10.1016/
j.diabres.2019.02.014.
[45] FEI Y，TSOI M F，CHEUNG B. Cardiovascular
outcomes in trials of new antidiabetic drug classes：a
network meta-analysis[J]. Cardiovasc Diabetol，2019，
18（1）：112.
[46] DARSALIA V，LARSSON M，KLEIN T，et al. The
high need for trials assessing functional outcome
after stroke rather than stroke prevention with GLP-
1 agonists and DPP-4 inhibitors[J]. Cardiovasc
Diabetol，2018，17（1）：32.